Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency

Vaccine

Volumn 33, Issue 29, 2015, Pages 3392-3397

  Ravin, Nikolai V ^a   Blokhina, Elena A ^a   Kuprianov, Victor V ^a   Stepanova, Liudmila A ^b   Shaldjan, Aram A ^b   Kovaleva, Anna A ^b   Tsybalova, Liudmila M ^b   Skryabin, Konstantin G ^a  

^a INSTITUTE OF BIOENGINEERING   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

HBc particle; Influenza virus; M2e; Vaccine

Indexed keywords

HEPATITIS B CORE ANTIGEN; INFLUENZA VACCINE; M2E PROTEIN; MEMBRANE PROTEIN; RECOMBINANT M2E PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; EPITOPE; HYBRID PROTEIN; M2 PROTEIN, INFLUENZA A VIRUS; M2E-HBC INFLUENZA VACCINE; MATRIX PROTEIN; RECOMBINANT VACCINE; VIRUS LIKE PARTICLE VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DNA FLANKING REGION; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; IMMUNOBIOLOGY; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MAJOR IMMUNODOMINANT LOOP REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

ANIMALS; DISEASE MODELS, ANIMAL; EPITOPES; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HEPATITIS B CORE ANTIGENS; INFLUENZA VACCINES; MICE, INBRED BALB C; MUTAGENESIS, INSERTIONAL; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL MATRIX PROTEINS;

EID: 84931570544     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.066     Document Type: Article

References (33)

1. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56(1):152-179.
2. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M, et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
3. Lamb R.A., Choppin P.W. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 1981, 112(2):729-737.
4. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Min Jou W., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
5. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991, 65:5491-5498.
6. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A "universal" human influenza A vaccine. Virus Res 2004, 103:173-176.
7. Feng J.Q., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102.
8. Ionescu R.M., Przysiecki C.T., Liang X., Garsky V.M., Fan J., Wang B., et al. Pharmaceutical and immunological evaluation of human papillomavirus virus like particle as an antigen carrier. J Pharm Sci 2006, 95:70-79.
9. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395-3403.
10. Petukhova N.V., Gasanova T.V., Stepanova L.A., Rusova O.A., Potapchuk M.V., Korotkov A.V., et al. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco Mosaic Virus-based vectors. Curr Pharm Des 2013, 19:5587-5600.
11. Middelberg A.P.J., Rivera-Hernandez T., Wibowo N., Lua L.H.L., Fan Y., Magor G., et al. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 2011, 29:7154-7162.
12. Wibowo N., Chuan Y.P., Lua L.H.L., Middelberg A.P.J. Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 2013, 103:12-20.
13. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23:366-371.
14. Eliasson D.G., El Bakkouri K., Schon K., Ramne A., Festjens E., Löwenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26(9):1243-1252.
15. Huleatt J., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
16. Herve P.-L., Raliou M., Bourdieu C., Petit-Camurdan A., Bertho N., Eleouet J.-F., et al. A novel subnucleocapsid nanoplatform for vaccination against influenza virus that targets the of matrix protein 2. J Virol 2014, 88:325-338.
17. Wynne S.A., Crowther R.A., Leslie A.G. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999, 3:771-780.
18. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001, 44:98-114.
19. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262(5138):1448-1451.
20. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20:3104-3112.
21. Blokhina E.A., Kuprianov V.V., Tsybalova L.M., Kiselev O.I., Ravin N.V., Skryabin K.G. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. Virology 2013, 435:293-300.
22. Kratz P.A., Bottcher B., Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999, 96:1915-1920.
23. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18:329-337.
24. Vogel M., Vorreiter J., Nassal M. Quaternary structure is critical for protein display on capsid-like particles (CLPs): efficient generation of hepatitis B virus CLPs presenting monomeric but not dimeric and tetrameric fluorescent proteins. Proteins 2005, 58:478-488.
25. Ravin N.V., Kotlyarov R.Y., Mardanova E.S., Kuprianov V.V., Migunov A.I., Stepanova L.A., et al. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Moscow) 2012, 77:33-40.
26. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161.
27. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 2002, 168:4951-4959.
28. Ibanez L.I., Roose K., De Filette M., Schotsaert M., De Sloovere J., Roels S., et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS ONE 2013, 2013(8):e59081.
29. Robinson C.R., Sauer R.T. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci USA 1998, 95(11):5929-5934.
30. Skamel C., Ploss M., Bottcher B., Stehle T., Wallich R., Simon M.M., et al. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J Biol Chem 2006, 281(25):17474-17481.
31. Chuan Y.P., Rivera-Hernandez T., Wibowo N., Connors N.K., Wu Y., Hughes F.K., et al. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 2013, 110:2343-2351.
32. Kotlyarov R.Yu, Kupriyanov V.V., Migunov A.I., Stepanova L.A., Tsybalova L.M., Kiselev O.I., et al. Development of recombinant vaccine against A(H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein. Acta Naturae 2010, 2(2):71-77.
33. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Löwenadler B., et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.